C22-102-04 rHuEPO-α說明書

Catalog Number:  C22-102-04
Source:  CHO
Molecular Weight:  Mature human EPO, containing 166 amino acid residues, has a predicted molecular mass of
 approximately 21 kDa. As a result of glycosylation, the recombinant protein migrates with an
 apparent molecular mass of 36-40 kDa in SDS-PAGE.
Quantity:  500IU/2000IU/150000IU
AA Sequence:  APPRLICDSR VLERYLLEAK EAENITTGCA EHCSLNENIT VPDTKVNFYA
 WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQPWEP LQLHVDKAVS
 GLRSLTTLLR ALGAQKEAIS PPDAASAAPL RTITADTFRK LFRVYSNFLR
 GKLKLYTGEA CRTGDR
Purity:  >98% by SDS-PAGE and HPLC analyses.
Biological Activity:  Fully biologically active when compared to standard. The Specific Activity was measured by the
 stimulation of reticulocyte production in normocyth-aemic mice and was found to be no less than 1.5 ×105IU/mg.
Physical Appearance:  Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation:  Lyophilized from a 0.2μm filtered concentrated solution in sodium citrate buffer (1 liter of ddH2O
 containing 5.9 g of sodium citrate, 5.8 g of sodium chloride and 0.06 g of citric acid).
Endotoxin:  Less than 0.01EU/μg of rHuEPO-α as determined by LAL method.
Reconstitution:  We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
 bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a
 concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and
 stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.
Storage:  This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage,
 preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For
 maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to
 -70°C. Avoid repeated freeze/thaw cycles.
Usage:  This material is offered by Shanghai Corning Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Human Erythropoietin
Erythropoietin (EPO), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by
stimulating the proliferation and differentiation of erythroid progenitor cells. The production of EPO by kidney cells is increased
in response to hypoxia or anemia. Recombinant EPO has been approved for the treatment of anemia associated with chronic renal
failure as well as for anemia of AZT treated AIDS patients.